Study Details

Back
Study ID AGS67E-15-2
Study Title A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)
Clinicaltrials.gov Identifier NCT02610062
Compound Name AGS67E
Medical Indication or Disease Acute myeloid leukemia
Study Sponsor Astellas Pharma Development, Inc.
Collaborator Not Applicable
Study Start Date 29-Mar-2016
Study Completion Date 21-Nov-2017
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS